Pharmaceuticals, Biotechnology and Life Sciences
2021 Vaccine Manufacturing: Raises lower end of global manufacturing plan for 2021 from 600 million doses to 700 million doses; manufacturing is still working to supply up to 1 billion doses for 2021
2022 Vaccine Manufacturing: Based on the high dema…
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine
Discussi…
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases
KENILWORTH, N.J & WATERTOWN, Mass.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc….
BOULDER, Colo.–(BUSINESS WIRE)–#BDSX–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutto…
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has closed a $50 m…
DUBLIN–(BUSINESS WIRE)–The “Cannabis Pharmaceuticals Market Share, Size, Trends, Industry Analysis Report, By Product; By Distribution Channel; By Regions; Segment Forecast, 2020-2027” report has been added to ResearchAndMarkets.com’s offering.
The …
DUBLIN–(BUSINESS WIRE)–The “Human Immunodeficiency Virus (HIV) Therapeutics – Global Drug Forecast and Market Analysis to 2029” report has been added to ResearchAndMarkets.com’s offering.
The publisher projects the global HIV marketplace will experi…
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have prev…
Quarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020
Quarterly net income of $4.9 million with $0.05 in earnings per share
ST. HELIER, Jersey–(BUSI…
Two Phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated evaluating KarXT for the treatment of psychosis in adults with schizophrenia
Results from the Phase 2 EMERGENT-1 clinical trial of KarXT in schizophrenia published in the New England Journal of…